Anti CD-40 antibody glyco-optimised - Glycotope
Alternative Names: CD-40GEX®Latest Information Update: 28 Mar 2023
At a glance
- Originator Glycotope
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 05 Feb 2019 Anti CD-40 antibody glyco-optimised - Glycotope is available for licensing before 05 Feb 2019 (Glycotope pipeline, January 2019)
- 05 Feb 2019 Preclinical trials in Cancer in Germany (Parenteral) before February 2019 (Glycotope pipeline, February 2019)